603127 昭衍新药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,187,90620.60%1,657,6242,018,3342,376,4872,267,971
减:营业总成本1,128,45210.05%1,663,2151,763,7481,622,0101,418,766
    其中:营业成本861,82911.54%1,314,3121,444,5601,363,7011,181,660
               财务费用(39,850)-24.69%(66,802)(99,773)(151,091)(154,682)
               资产减值损失(23,581)-69.09%(156,761)(66,540)(31,232)(2,792)
公允价值变动收益971,478474.17%447,560(127,049)(245,642)349,567
投资收益9,464-52.76%18,01436,0129,62813,022
    其中:对联营企业和合营企业的投资收益------15,471(3,069)(2,691)
营业利润1,018,258923.87%337,991104,347507,0961,225,639
利润总额1,018,159921.99%337,493104,039506,9501,240,002
减:所得税费用88,470367.62%39,65134,284115,398166,802
净利润929,6881,051.94%297,84369,755391,5531,073,200
减:非控股权益1-6,731.87%1(4,320)(5,440)(1,057)
股东净利润929,6871,051.94%297,84174,075396,9931,074,257

市场价值指针
每股收益 (元) *1.2501,036.36%0.4000.1000.5301.440
每股派息 (元) *----0.1200.0300.1600.400
每股净资产 (元) *12.23212.89%11.10810.77911.04015.277
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容